Phase @ was a double-blind study that randomly assigned patients ( @:@:@ ) using an interactive voice response system to receive rilotumumab @ mg/kg , rilotumumab @ mg/kg , or placebo , plus ECX ( doses as above ) , stratified by ECOG performance status and disease extent .